Nano & Microparticle Drug Delivery: How will it play a role in peripheral arterial interventions Subhash Banerjee, MD Associate Prof. of Medicine UT Southwestern.

Slides:



Advertisements
Similar presentations
M.Unverdorben; ACC March 2008 Martin Unverdorben Rotenburg/Fulda, Germany and Richmond, VA, USA Clinical Research Institute, Center for Cardiovascular.
Advertisements

Drug Coated Balloons From Bench to Bedside Service de Radiodiagnostic et Radiologie Interventionnelle Université de Lausanne Salah D. Qanadli, MD, PhD,
Θεματική ενότητα: Stenting Μ. Ματσάγκας, MD, PhD, FEBVS Σάββατο 9 Φεβρουαρίου 2013.
Applications of Nanoparticles for Delivery of Therapeutic Agents Frank Jeyson Hernández Topics of Nanobiotechnology 30 June, 2004.
Disclosure Statement Consultant for ThermopeutiX, Inc. Stockholder of ThermopeutiX, Inc. Snowmass 2014.
Therapeutic Peptides for Cardiovascular Disease and Cancer Cam Patterson, MD, MBA, FACC, FAHA Ernest and Hazel Craige Distinguished Professor of Cardiovascular.
Laura Schmidt, PHY335, Dec. 2, 2003 Selective withdrawal using non-Newtonian fluids The process: withdrawing fluid through a pipette positioned above a.
Angioplasty’s Fight against Restenosis: Drug Eluting Stents & Bare Metal Stents.
Vascular wall biology with current generation stents Professor Martin Bennett BHF Professor of Cardiovascular Sciences, Cambridge.
Targeted Gold Nanoparticles as Vascular Disrupting Agents during Radiation Therapy RI Berbeco 1, H Korideck 1, S Kunjachan 1, R Kumar 2, S Sridhar 2, A.
M.Unverdorben; TCT Problem The treatment of stenoses of small coronary arteries (SVD) and of restenoses after stent deployment (ISR) still show.
The Science Behind Taxus Advanced Angioplasty 2004 Christian Vander Velde, Boston Scientific Europe, Marketing.
NANOPARTICLES FOR DRUG DELIVERY: THE SMALLER, THE BETTER ? Gurny R., Pourtier M., Vargas A., Delie F. Department of Pharmaceutics and Biopharmaceutics.
Medtronic CardioVascular Interventional Pipeline 1.
Session 5: Targeted Drug Delivery Drug delivery to target tissues: principles and mechanisms Prof. Dr. Paul Debbage Medical University Innsbruck.
W. Mark Saltzman Yale University Biomaterials, Drug Delivery, and Tissue Engineering.
Magnetically-Guided Nanoparticle Drug Delivery Seth Baker, RET Fellow 2011 Percy Julian Middle School RET Mentor: Prof. Andreas A. Linninger Chicago Science.
The origin of post-injury neointimal cells in the rat balloon injury model by Luis Rodriguez-Menocal, Melissa St-Pierre, Yuntao Wei, Sheik Khan, Dania.
Abstract Polymeric Porous microspheres are an effective drug delivery mechanism able to control drug release, preventing drug wastage and lowering costs.
Drug Coated Balloons for PAD William B. Newton III, MD Assistant Professor of Surgery Department of Vascular and Endovascular Surgery.
TGF-β1 Release from Biodegradable Polymer Microparticles: Its Effects on Marrow Stromal Osteoblast Function by Lichun Lu, Michael J. Yaszemski, and Antonios.
Modular Nanodevices for Creation of Smart Adaptable Vaccine Delivery Vehicles Tarek M. Fahmy Dept. of Biomedical Engineering, Yale University Several key.
A Comparison of the Moxy™ Drug Coated Balloon Catheter vs. Standard PTA for Femoropopliteal Disease NCT# MONTH RESULTS OF THE LEVANT I TRIAL.
SONG XIANTAO MD Beijing Anzhen Hospital affiliated to Capital Medical University.
Use of Photoactivated Crosslinking Agents for Vascular Repair and Local Drug Delivery Kaia L. Kloster, Ph.D. Avera Research Institute PhotoBioMed Corporation.
Date of download: 6/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Magnetic Tagging Increases Delivery of Circulating.
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: An Endocrine Genetic Signal Between Blood Cells.
DES arena THE CURRENT APPROACH TO DES MARKET IS BASED ON DRUG
November 9, 2015 February 20, 2017 Using real world evidence – industry perspective Pma indication expansion Melissa hasenbank, phd Sr. Clinical Research.
DRug Eluting Bbsorbable Metal Scaffold (DREAMS)
Abbott Vascular Bifurcation Program
Regulatory Considerations for Coronary Drug Coated Balloons (DCBs)
The (Potential) Role of Drug Eluting Balloons in BTK Interventions
Novel Devices Focus – The Path Forward for DEB and New DES and Bioabsorbable Stents Academic View Bruno Scheller, MD Klinische und Experimentelle Interventionelle.
Paclitaxel Drug-Coated Balloons for De Novo Lesions
Magnetite Nanoparticles Testing Magnetic Susceptibility
One DES Eluting Two Drugs: Is it Feasible?
Future Directions and Development of DCB Systems
Subhash Banerjee, MD Associate Prof. of Medicine
Drug Eluting Balloons Bodo Cremers, MD
Zoledronate Inhibits Intimal Hyperplasia in Balloon-injured Rat Carotid Artery  L. Wu, L. Zhu, W.H. Shi, B. Yu, D. Cai  European Journal of Vascular and.
Regulatory Considerations for Coronary Drug Coated Balloons – FDA View
Role for Hyaluronan Synthase 3 in the Response to Vascular Injury
Arterioscler Thromb Vasc Biol
The OrbusNeich EPC Capture Biodegradable Polymer Sirolimus-eluting Stent Program Michael JB Kutryk, MD, PhD St Michael’s Hospital, Toronto.
AcoArt I Trial design: Patients with femoropopliteal artery disease were randomized to paclitaxel-coated balloon angioplasty (n = 100) vs. standard peripheral.
In vivo PEG modification of vascular surfaces for targeted delivery
Paclitaxel coating on the terminal portion of hemodialysis grafts effectively suppresses neointimal hyperplasia in a porcine model  Insu Baek, PhD, Jinsun.
Inhibitory effects of mesenchymal stem cells in intimal hyperplasia after balloon angioplasty  Ae-Kyeong Kim, PhD, Min-Hee Kim, Do-Hyung Kim, Ha-Nl Go,
Lysyl oxidase expression in a rat model of arterial balloon injury
FAIR Trial design: Patients with SFA in-stent restenosis (ISR) were randomized to either a paclitaxel-coated balloon (DCB) (dose 3.5 μg/mm2) or routine.
Interleukin 18 binding protein (IL18-BP) inhibits neointimal hyperplasia after balloon injury in an atherosclerotic rabbit model  Jian-Ming Li, MD, Mohammad.
ILLUMENATE Trial design: Patients with superficial femoral artery (SFA) and/or popliteal arterial stenoses were randomized in a 2:1 fashion to either balloon.
Adenovirus-mediated intra-arterial delivery of cellular repressor of E1A-stimulated genes inhibits neointima formation in rabbits after balloon injury 
Fig 6.1 Drug released by diffusion
Thomas E. Arnold, MD, Dmitri Gnatenko, PhD, Wadie F. Bahou, MD 
Inhibition of neointimal hyperplasia by blocking αvβ3 integrin with a small peptide antagonist GpenGRGDSPCA*  Eric T. Choi, MD, Leslie Engel, PhD, Allan.
Tissue factor pathway inhibitor-2 is induced by fluid shear stress in vascular smooth muscle cells and affects cell proliferation and survival  Johan.
CD34 affinity pheresis attenuates a surge among circulating progenitor cells following vascular injury  Adriana Harbuzariu, MD, Justine Kim, BS, E. Michael.
Improved retroviral transduction efficiency of vascular cells in vitro and in vivo during clinically relevant incubation periods using centrifugation.
Paclitaxel coating of the luminal surface of hemodialysis grafts with effective suppression of neointimal hyperplasia  Insu Baek, MS, Cheng Zhe Bai, PhD,
Marcel Scheinman, MD, Enrico Ascher, MD, Gabriel S
Inhibition of experimental neointimal hyperplasia by recombinant human thrombomodulin coated ePTFE stent grafts  Geoffrey Wong, MD, Jian-ming Li, MD,
Perivascular delivery of losartan with surgical fibrin glue prevents neointimal hyperplasia after arterial injury  Michael C Moon, MD, Katerina Molnar,
The effects of low-dose radiation on neointimal hyperplasia
Fig. 2. CD31 provides robust NP targeting in vitro but slow kinetics.
Integrin αvβ3 as a target in the prevention of neointimal hyperplasia
Laura Z. Vanags et al. BTS 2018;3:
Neointimal hyperplasia in balloon-injured rat carotid arteries: The influence of hyperhomocysteinemia  Judith W. Cook, MDa,b, M.Rene Malinow, MDc, Gregory.
Artificial Zinc-Finger Transcription Factor of A20 Suppresses Restenosis in Sprague Dawley Rats after Carotid Injury via the PPARα Pathway  Zhaoyou Meng,
Presentation transcript:

Nano & Microparticle Drug Delivery: How will it play a role in peripheral arterial interventions Subhash Banerjee, MD Associate Prof. of Medicine UT Southwestern Med. Ctr. Nov. 2013

Drug Coated Balloon (DCB) for Peripheral Arterial Interventions  Success of DCB relies on the rapid transfer of a single dose of an anti-proliferative agent into the vessel wall  The dominant challenge for DCB is rapid, uniform, efficient, & directed transfer of the drug to the vessel wall during balloon inflation with limited downstream distribution  Tissue delivery=8.8±3.9% of the mean percentage of total original catheter load Cremers et al. Thromb Haemost. 2009; 101: 201–206

Drug Concentration of Current DCB Waxman et al. JACC Cardiovasc Interv.2012; 5: DCB 6x60 mm; 1 inflation=3391 µg Paclitaxel coated balloon= Low-dose (0.2 μg/stent) Intermediate-dose (15 μg/stent) High-dose (187 μg/stent) Heldman et al. Circulation. 2001; 103: DCB 6x60 mm; 1 inflation=3391 µg Paclitaxel coated balloon= Low-dose (0.2 μg/stent) Intermediate-dose (15 μg/stent) High-dose (187 μg/stent) Heldman et al. Circulation. 2001; 103:

Multi-Ligand Nanoparticles (MLNP) Paclitaxel  “Platelet mimicking”  Poly (L-lactic-co-glycolic acid) (PLGA)  Surface conjugated ligands:  polyethylene glycol (PEG)  glycoprotein 1b (GP1b)  trans-activating transcriptional peptide (TAT)  Extensive biocompatibility testing Banerjee et al. J Cardiovasc Transl Res Aug;6(4):570-8

MLNP Uptake by Injured Endothelial Cells (EC) Banerjee et al. J Cardiovasc Transl Res Aug;6(4):570-8 PLGA-PEGPLGA-PEG-Gp1bPLGA-PEG-Gp1b/TAT Under flow conditions EC delivery

Drug Delivering MLNP Coated Balloon Xu Hao et al. TCT 2013 Fluorescent Image of Nanoparticle- coated Angioplasty Balloon Tip Nanoparticle-coated balloon surface after inflation/deflation Uncoated angioplasty balloon surface Nanoparticle-coated balloon surface before inflation Surface SEM of Nanoparticle- coated Angioplasty Balloon

Transfer of MLNP Coated Angioplasty Balloon to Rat Artery Banerjee et al. J Cardiovasc Transl Res Aug;5(4): A.Angioplasty balloon without coating of nanoparticles B.Angioplasty balloon coated with nanoparticles before inflation C.Angioplasty balloon coated with nanoparticles after inflation-deflation D.Rat carotid artery before angioplasty E.Rat carotid artery after angioplasty 7% particles were transferred to the artery wall 27% particles were lost

Paciltaxel-Loaded MLNP Suppresses Rat Carotid Artery Neointima Banerjee et al. J Cardiovasc Transl Res. (in submission) Uninjured Normal saline Nanoparticles w/o paclitaxel Paclitaxel solution Paclitaxel- loaded nanoparticle Rat Carotid Balloon Injury Model

Paciltaxel-Loaded MLNP Suppresses Rat Carotid Artery Neointima Banerjee et al. J Cardiovasc Transl Res. (in submission)

Drug Concentration of DCB

MLNP Loaded DCB for Peripheral Arterial Interventions  Paclitaxel containing biodegradable, MLNP can be loaded on angioplasty balloons & delivered reliably to injured vascular surfaces with demonstrable suppression of neointimal proliferation  MLNP-DCB may potentially offer a pathway for targeted drug delivery to injured vascular wall, at significantly reduced doses  Future studies to refine the technology, assess comparative efficacy & safety are on-going